Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Capstone Energy+ increases production for data centers and expands manufacturing capacity

Capstone Energy+ reports rising demand from data centers and has expanded manufacturing in Van Nuys from 2 MW to 7 MW per week in single‑shift operation; in two shifts annual capacity could exceed 700 MW. The company highlights its low‑maintenance turbine design, is working on 800‑V‑DC compatibility, lower emissions, a restart of the C250 engine, and a roadmap to 500 kW/1 MW systems. Capstone sees near‑term growth in data centers but also aims to address ports, utilities and substations and is focusing on KWK/KWKK with high heat‑recovery efficiency. After an earlier Chapter‑11 proceeding, management is working with Monarch to clean up the capital structure and expects improvements within about six months. » More on de.investing.com
Capstone secures $10 million convertible note to finance acquisitions

Capstone Holding Corp. has secured a $10 million convertible note facility to fund its acquisition strategy and drive growth. The first tranche of $3 million will be used to acquire a distributor in the southeastern United States, while the company reaffirms its financial targets for 2025. CEO Matt Lipman highlights the flexibility of the financing and the goal to increase revenue to $100 million. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 1998, CAPSTONE THERAP. DL-,0005 has already paid €0.11 in dividends. The last payout was in May 1998.

Financials

In the last quarter, CAPSTONE THERAP. DL-,0005 had revenue of €18.82m and net profit of -€1.21m

(EUR)	June 2026	YoY
Revenue	18.82m	72.61%
Gross profit	5.26m	97.94%
Net profit	-1.21m	103.60%
EBITDA	2.31m	1,964.62%

Fundamentals

Metric	Value
Market capitalization	€2.32m
Number of shares	15.2m
52-week high/low	€1.31 - €0.15
Dividends	No
Beta	-1.50
P/E ratio	-0.05
PEG ratio	0.00
P/B ratio	0.18
P/S ratio	0.04

Company profile

Capstone Therapeutics Corp. ist ein Biotechnologieunternehmen, das neuartige Peptide und andere Moleküle zur Unterstützung von Patienten mit unterversorgten Krankheiten in den Vereinigten Staaten entwickelt. Es entwickelt das Apo-E-mimetische Peptidmolekül AEM-28 und seine Analoga, die klinische Studien der Phase Ia und der Phase Ib/IIa für den Lipoproteinstoffwechsel abgeschlossen haben. Das Unternehmen war früher als OrthoLogic Corp. bekannt und änderte im Mai 2010 seinen Namen in Capstone Therapeutics Corp. Capstone Therapeutics Corp. wurde 1987 gegründet und hat seinen Hauptsitz in Tempe, Arizona.